Live
FierceBiotechFDA approves Denali's Hunter syndrome drug, handing rare disease community a winBioPharma DiveMaze tumbles on positive data for kidney disease drugEndpoints NewsFDA gives Denali accelerated approval for rare disease drug10x Genomics BlogVanguard realigns reporting; subsidiaries to report TXG holdings (TXG) - Stock TitanEndpoints NewsMore changes ahead for Takeda with new CEO set to take reins10x Genomics BlogWhy 10x Genomics Stock Is Surging Right Now - TipRanksEndpoints NewsHow Seaport is hedging against failure in Phase 2b depression studyBioPharma DiveBeam posts positive data on base editing treatment for AATDThermo FisherThermo Fisher, SHL Medical collab on drug delivery device production - Drug Delivery BusinessEndpoints NewsFDA approves Corcept's Lifyorli for ovarian cancer months earlyIlluminaSave your collagen and 50% off the red light therapy mask I’d pay full price for - New York PostFierceBiotechSarepta's big bet on Arrowhead's siRNA assets yields early data
Endpoints News Jan 5, 2026

Aktis Oncology eyes $181M listing to start industry’s anticipated IPO rebound

Aktis Oncology eyes $181M listing to start industry’s anticipated IPO rebound

Original
Body unavailable. Use the original source.

Directory

59 All